Galaxy Surfactants

₹2470 15.2 | 0.6%

WEBSITE BSE:540935 NSE : GALAXYSURF 10 May, 16:01

Market Cap ₹8757 Cr.

Stock P/E 27.8

P/B 4.2

Current Price ₹2470

Book Value ₹ 592.5

Face Value 10

52W High ₹2979

Dividend Yield 0.89%

52W Low ₹ 2241.1

Edit Ratio

Galaxy Surfactants Research see more...

Overview Inc. Year: 1986Industry: Household & Personal Products

Galaxy Surfactants Ltd is an primarily India-based chemical manufacturing enterprise, that is engaged in production and advertising surfactants and speciality chemical substances for home care industry and personal. Its market section include skin care, hair care, sun care, oral care, infant care and domestic care. Its merchandise consist of fatty alcohol sulfate and ether sulphate, fatty alcohol ethoxylate & labsa, foam & viscosity boosters, moderate surfactants, pearlizers, surfactant blends, syndet & TBB, sunscreens, functional actives, preservatives and blends. Its variety of merchandise include Galsoft series, Galaxy Benzalkonium Chloride, Galaxy PEG 7 GC, and Galguard. Its products are used in home care, hand wash and well being. The Company operates in India, United States and Egypt.

Galaxy Surfactants Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Galaxy Surfactants Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	877	929	1053	1163	1236	1085	974	942	983	940
Other Income	5	2	1	-2	1	4	7	2	3	6
Total Income	882	931	1054	1161	1238	1089	982	944	986	947
Total Expenditure	806	853	908	1015	1105	931	840	819	858	828
Operating Profit	76	78	146	146	133	158	142	126	128	119
Interest	4	3	3	4	6	6	6	6	5	6
Depreciation	18	18	18	19	20	22	23	24	25	25
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	54	58	124	123	107	131	113	96	98	88
Provision for Tax	12	12	26	22	23	24	22	21	20	16
Profit After Tax	42	46	98	100	84	106	91	75	77	71
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	42	46	98	100	84	106	91	75	77	71
Adjusted Earnings Per Share	11.8	12.9	27.8	28.3	23.7	30	25.5	21.2	21.8	20.1

Galaxy Surfactants Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	1580	1697	1872	1801	2161	2434	2763	2596	2784	3686	4445	3839
Other Income	3	4	4	6	10	10	11	7	12	14	11	18
Total Income	1582	1701	1875	1807	2172	2444	2774	2604	2796	3699	4456	3859
Total Expenditure	1461	1479	1681	1568	1890	2146	2416	2229	2337	3286	3878	3345
Operating Profit	121	222	194	240	282	298	358	375	460	413	578	515
Interest	52	44	37	33	27	31	30	24	13	13	22	23
Depreciation	50	55	45	45	47	49	51	62	74	71	83	97
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	19	122	113	161	207	219	277	289	372	329	473	395
Provision for Tax	18	47	45	60	60	61	86	58	70	67	92	79
Profit After Tax	0	75	68	101	148	158	191	230	302	263	381	314
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	0	75	68	101	148	158	191	230	302	263	381	314
Adjusted Earnings Per Share	0.1	21.2	19.2	28.5	41.6	44.6	53.9	65	85.2	74.1	107.5	88.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	21%	20%	13%	11%
Operating Profit CAGR	40%	16%	14%	17%
PAT CAGR	45%	18%	19%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	-1%	-5%	19%	NA%
ROE Average	22%	22%	23%	22%
ROCE Average	24%	23%	24%	22%

Galaxy Surfactants Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	237	305	361	442	575	719	877	1068	1301	1574	1883
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	222	204	141	194	128	72	89	117	77	80	89
Other Non-Current Liabilities	31	30	28	29	30	32	38	58	50	77	76
Total Current Liabilities	465	484	527	435	549	629	559	569	620	865	680
Total Liabilities	954	1023	1057	1100	1283	1452	1563	1812	2049	2597	2728
Fixed Assets	456	474	459	436	456	447	519	748	712	760	923
Other Non-Current Assets	47	32	32	81	71	86	147	129	179	266	202
Total Current Assets	452	516	566	584	756	919	897	935	1158	1570	1602
Total Assets	954	1023	1057	1100	1283	1452	1563	1812	2049	2597	2728

Galaxy Surfactants Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	12	12	16	14	15	26	27	25	48	82	64
Cash Flow from Operating Activities	55	155	41	170	111	145	283	316	365	5	573
Cash Flow from Investing Activities	-53	-42	-26	-59	-43	-55	-167	-151	-165	-84	-149
Cash Flow from Financing Activities	-2	-108	-17	-110	-57	-90	-119	-144	-165	59	-264
Net Cash Inflow / Outflow	-0	4	-2	0	11	1	-4	21	35	-20	160
Closing Cash & Cash Equivalent	12	16	14	14	26	27	25	48	82	64	232

Galaxy Surfactants Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	0.08	21.23	19.18	28.53	41.64	44.58	53.87	65	85.23	74.13	107.47
CEPS(Rs)	14.18	36.82	31.9	41.28	54.94	58.27	68.32	82.54	106.09	94.17	131.02
DPS(Rs)	1	4	4	6	6	7	8	14	18	18	22
Book NAV/Share(Rs)	66.9	86.01	101.73	124.6	162.17	202.76	247.31	301.2	367.11	444.1	531.04
Core EBITDA Margin(%)	7.12	12.29	9.76	12.49	12.07	11.68	12.57	14.15	16.07	10.84	12.76
EBIT Margin(%)	4.27	9.41	7.64	10.38	10.44	10.12	11.11	12.04	13.86	9.28	11.13
Pre Tax Margin(%)	1.13	6.93	5.76	8.63	9.23	8.88	10.02	11.12	13.37	8.93	10.64
PAT Margin (%)	0.02	4.26	3.48	5.41	6.57	6.42	6.91	8.87	10.85	7.13	8.57
Cash Profit Margin (%)	3.03	7.38	5.79	7.82	8.66	8.39	8.77	11.27	13.51	9.06	10.45
ROA(%)	0.03	7.61	6.54	9.38	12.39	11.56	12.67	13.65	15.65	11.31	14.31
ROE(%)	0.12	27.76	20.43	25.21	29.04	24.43	23.94	23.7	25.51	18.28	22.04
ROCE(%)	10.49	23.22	19.46	23.36	25.79	24.51	27.38	23.92	25.63	19.5	24.16
Receivable days	36.64	39.35	39.76	45.99	48.5	56.73	55.81	60.88	59.54	54.81	51.44
Inventory Days	45.28	42.98	44.49	46.99	44.91	49.14	46.03	47.54	49.35	56.43	55.74
Payable days	65.08	62.96	57.57	57.52	54.73	62.79	61.3	63.73	69.32	65.08	57.48
PER(x)	0	0	0	0	0	33.65	19.84	18.04	29.98	38.66	21.71
Price/Book(x)	0	0	0	0	0	7.4	4.32	3.89	6.96	6.45	4.39
Dividend Yield(%)	0	0	0	0	0	0.47	0.75	1.19	0.7	0.63	0.94
EV/Net Sales(x)	0.31	0.25	0.25	0.24	0.19	2.32	1.47	1.72	3.31	2.84	1.87
EV/Core EBITDA(x)	4.1	1.95	2.41	1.79	1.43	18.93	11.34	11.94	20.05	25.3	14.35
Net Sales Growth(%)	15.09	7.41	10.32	-3.76	19.98	12.61	13.52	-6.03	7.23	32.39	20.61
EBIT Growth(%)	-20.23	134.81	-10.29	30.19	20.77	6.26	23.07	1.89	23.38	-11.3	44.57
PAT Growth(%)	-99.12	0	-9.65	48.74	45.97	7.05	20.85	20.65	31.13	-13.03	44.98
EPS Growth(%)	-99.12	0	-9.65	48.74	45.97	7.05	20.85	20.65	31.13	-13.03	44.98
Debt/Equity(x)	2	1.37	1.25	0.93	0.68	0.48	0.34	0.35	0.21	0.23	0.14
Current Ratio(x)	0.97	1.07	1.07	1.34	1.38	1.46	1.61	1.64	1.87	1.81	2.36
Quick Ratio(x)	0.57	0.59	0.61	0.8	0.8	0.91	0.98	1.07	1.18	0.99	1.41
Interest Cover(x)	1.36	3.79	4.07	5.92	8.62	8.16	10.23	13.14	28.74	26.63	22.79
Total Debt/Mcap(x)	0	0	0	0	0	0.07	0.08	0.09	0.03	0.04	0.03

Galaxy Surfactants Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	70.93	70.93	70.93	70.93	70.93	70.93	70.93	70.92	70.92	70.91
FII	2.05	1.89	2.01	2.82	2.78	2.9	2.99	3.07	3.61	3.76
DII	13.37	13.78	13.62	12.73	12.72	12.66	12.65	12.57	12.44	12.73
Public	13.65	13.4	13.44	13.52	13.58	13.51	13.44	13.44	13.03	12.6
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	2.51	2.51	2.51	2.51	2.51	2.51	2.51	2.51	2.51	2.51
FII	0.07	0.07	0.07	0.1	0.1	0.1	0.11	0.11	0.13	0.13
DII	0.47	0.49	0.48	0.45	0.45	0.45	0.45	0.45	0.44	0.45
Public	0.48	0.48	0.48	0.48	0.48	0.48	0.48	0.48	0.46	0.45
Others	0	0	0	0	0	0	0	0	0	0
Total	3.55	3.55	3.55	3.55	3.55	3.55	3.55	3.55	3.55	3.55

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 22%
Debtor days have improved from 65.08 to 57.48days.
Company is almost debt free.

Cons

Stock is trading at 4.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.